文献速递临床试验与 GCP真实世界研究与卫生经济

持续葡萄糖监测对老年1型糖尿病患者低血糖的影响:随机临床试验

Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

这项在美国22个内分泌诊所开展的随机临床试验纳入203例60岁及以上1型糖尿病患者,1:1分配至持续葡萄糖监测(CGM)组或标准血糖监测(BGM)组。6个月随访显示,CGM组血糖低于70 mg/dL的时间比例较BGM组降低1.9%(95%CI -2.8%至-1.1%,P<.001),HbA1c降幅多0.3%(95%CI -0.4%至-0.1%,P<.001),但认知与患者报告结局均无显著差异。

要点

  • ≥60岁1型糖尿病患者使用CGM 6个月,低血糖时间比例较BGM降低1.9%。
  • CGM组HbA1c较BGM组多降0.3%,9项CGM指标全部显著改善。
  • 认知功能和患者报告结局未见显著差异,长期获益尚需研究。

核心结论

  • 在60岁及以上1型糖尿病患者中,与标准血糖监测相比,持续葡萄糖监测在6个月内使低血糖获得小幅但有统计学意义的改善。

研究设计与样本

  • 研究为在美国22个内分泌诊所开展的随机临床试验,纳入203例60岁及以上1型糖尿病患者。
  • 参与者按1:1随机分配至CGM组(n=103)或标准BGM组(n=100)。
  • 主要结局为6个月随访期间CGM测得的传感器葡萄糖低于70 mg/dL的时间百分比。

主要发现

  • CGM组血糖低于70 mg/dL的中位时间比例从基线5.1%(73分钟/天)降至随访时2.7%(39分钟/天),BGM组从4.7%(68分钟/天)变为4.9%(70分钟/天)。
  • 校正后治疗差异为-1.9%(-27分钟/天),95%CI -2.8%至-1.1%(-40至-16分钟/天),P<.001。
  • 31项预设次要终点中,9项CGM指标全部、7项HbA1c结局中的6项差异有统计学意义,15项认知与患者报告结局均无统计学显著差异。
  • CGM组平均HbA1c较BGM组多降低0.3%(95%CI -0.4%至-0.1%,P<.001)。

临床怎么用

  • 对于60岁及以上1型糖尿病患者,可考虑使用CGM以小幅减少低血糖时间并改善血糖控制。

局限性

  • 研究仅随访6个月,低血糖改善幅度较小,长期临床获益仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypoglycemia in older adults with type 1 diabetes. OBJECTIVE: To determine whether CGM is effective in reducing hypoglycemia compared with standard blood glucose monitoring (BGM) in older adults with type 1 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 22 endocrinology practices in the United States among 203 adults at least 60 years of age with type 1 diabetes. INTERVENTIONS: Participants were randomly assigned in a 1:1 ratio to use CGM (n = 103) or standard BGM (n = 100). MAIN OUTCOMES AND MEASURES: The primary outcome was CGM-measured percentage of time that sensor glucose values were less than 70 mg/dL during 6 months of follow-up. There were 31 prespecified secondary outcomes, including additional CGM metrics for hypoglycemia, hyperglycemia, and glucose control; hemoglobin A1c (HbA1c); and cognition and patient-reported outcomes, with adjustment for multiple comparisons to control for false-discovery rate. RESULTS: Of the 203 participants (median age, 68 [interquartile range {IQR}, 65-71] years; median type 1 diabetes duration, 36 [IQR, 25-48] years; 52% female; 53% insulin pump use; mean HbA1c, 7.5% [SD, 0.9%]), 83% used CGM at least 6 days per week during month 6. Median time with glucose levels less than 70 mg/dL was 5.1% (73 minutes per day) at baseline and 2.7% (39 minutes per day) during follow-up in the CGM group vs 4.7% (68 minutes per day) and 4.9% (70 minutes per day), respectively, in the standard BGM group (adjusted treatment difference, -1.9% (-27 minutes per day); 95% CI, -2.8% to -1.1% [-40 to -16 minutes per day]; P <.001). Of the 31 prespecified secondary end points, there were statistically significant differences for all 9 CGM metrics, 6 of 7 HbA1c outcomes, and none of the 15 cognitive and patient-reported outcomes. Mean HbA1c decreased in the CGM group compared with the standard BGM group (adjusted group difference, -0.3%; 95% CI, -0.4% to -0.1%; P <.001). The most commonly reported adverse events using CGM and standard BGM, respectively, were severe hypoglycemia (1 and 10), fractures (5 and 1), falls (4 and 3), and emergency department visits (6 and 8). CONCLUSIONS AND RELEVANCE: Among adults aged 60 years or older with type 1 diabetes, continuous glucose monitoring compared with standard blood glucose monitoring resulted in a small but statistically significant improvement in hypoglycemia over 6 months. Further research is needed to understand the long-term clinical benefit. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03240432.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Pratley RE, Kanapka LG, Rickels MR, et al. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020. PMID: 32543682. doi:10.1001/jama.2020.6928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。